secukinumab

The Therapeutic Potential of Secukinumab in Rheumatic Diseases

The Therapeutic Potential of Secukinumab in Rheumatic Diseases

A review by Marije Koenders in Drug Design, Development and Therapy outlines some major features and characteristics of the new biological Secukinumab, which blocks the actions of interleukin 17A (IL-17), and explores its development, therapeutic potential and use in several rheumatic diseases. IL-17 provides protection against extracellular bacterial and fungal infections. However, IL-17 and Th17 […]

Secukinumab (Selective IL-17A Inhibitor) Shows Promise as a New Treatment for Ankylosing Spondylitis

Secukinumab (Selective IL-17A Inhibitor) Shows Promise as a New Treatment for Ankylosing Spondylitis

According to the Arthritis Foundation (Atlanta, GA), studies presented at this year’s American College of Rheumatology annual meeting in Boston (November 14–19) indicate that treatment with secukinumab may turn out to be a promising new therapeutic approach in ankylosing spondylitis (AS). Secukinumab (a fully human antibody to IL-17A), selectively binds to and neutralizes interleukin (IL)-17A, […]